+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Premature Ejaculation Treatment Market 2022-2026

  • PDF Icon

    Report

  • 120 Pages
  • July 2022
  • Region: Global
  • TechNavio
  • ID: 5309558
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The premature ejaculation treatment market is poised to grow by $1.26 bn during 2022-2026, accelerating at a CAGR of 9.06% during the forecast period. The report on the premature ejaculation treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the high efficacy of off-label drugs, demand for topical drug therapies for premature ejaculation treatment, and growing risk factors causing premature ejaculation.

The premature ejaculation treatment market analysis includes the route of administration segment and geographic landscape.

The premature ejaculation treatment market is segmented as below:


By Route of Administration

  • Oral
  • Topical

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the advent of nanotechnology as one of the prime reasons driving the premature ejaculation treatment market growth during the next few years. Also, increasing research and development and the emergence of novel devices will lead to sizable demand in the market.

The report on the premature ejaculation treatment market covers the following areas:

  • Premature ejaculation treatment market sizing
  • Premature ejaculation treatment market forecast
  • Premature ejaculation treatment market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading premature ejaculation treatment market vendors including A. Menarini Industrie Farmaceutiche Riunite Srl, Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., ANI Pharmaceuticals Inc., Aytu BioPharma Inc., Bayer AG, Cipla Ltd., Eli Lilly and Co., Endurance RP Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Lupin Ltd., NeuroHealing Pharmaceuticals Inc., Novitium Pharma, Pfizer Inc., Plethora Solutions Ltd., Sandoz International GmbH, Solco Healthcare, and Teva Pharmaceutical Industries Ltd. Also, the premature ejaculation treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market through study, synthesis, and summation of data from multiple sources by analyzing key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
Exhibit 14: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
4.1 Five forces summary
Exhibit 18: Five forces analysis - Comparison between 2021 and 2026
4.2 Bargaining power of buyers
Exhibit 19: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
4.3 Bargaining power of suppliers
Exhibit 20: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
4.4 Threat of new entrants
Exhibit 21: Threat of new entrants - Impact of key factors in 2021 and 2026
4.5 Threat of substitutes
Exhibit 22: Threat of substitutes - Impact of key factors in 2021 and 2026
4.6 Threat of rivalry
Exhibit 23: Threat of rivalry - Impact of key factors in 2021 and 2026
4.7 Market condition
Exhibit 24: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Route of Administration
5.1 Market segments
Exhibit 25: Chart on Route of Administration - Market share 2021-2026 (%)
Exhibit 26: Data Table on Route of Administration - Market share 2021-2026 (%)
5.2 Comparison by Route of Administration
Exhibit 27: Chart on Comparison by Route of Administration
Exhibit 28: Data Table on Comparison by Route of Administration
5.3 Oral - Market size and forecast 2021-2026
Exhibit 29: Chart on Oral - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Data Table on Oral - Market size and forecast 2021-2026 ($ million)
Exhibit 31: Chart on Oral - Year-over-year growth 2021-2026 (%)
Exhibit 32: Data Table on Oral - Year-over-year growth 2021-2026 (%)
5.4 Topical - Market size and forecast 2021-2026
Exhibit 33: Chart on Topical - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Data Table on Topical - Market size and forecast 2021-2026 ($ million)
Exhibit 35: Chart on Topical - Year-over-year growth 2021-2026 (%)
Exhibit 36: Data Table on Topical - Year-over-year growth 2021-2026 (%)
5.5 Market opportunity by Route of Administration
Exhibit 37: Market opportunity by Route of Administration ($ million)
6 Market Segmentation by Drug Class
6.1 Market segments
Exhibit 38: Chart on Drug Class - Market share 2021-2026 (%)
Exhibit 39: Data Table on Drug Class - Market share 2021-2026 (%)
6.2 Comparison by Drug Class
Exhibit 40: Chart on Comparison by Drug Class
Exhibit 41: Data Table on Comparison by Drug Class
6.3 SSRIs - Market size and forecast 2021-2026
Exhibit 42: Chart on SSRIs - Market size and forecast 2021-2026 ($ million)
Exhibit 43: Data Table on SSRIs - Market size and forecast 2021-2026 ($ million)
Exhibit 44: Chart on SSRIs - Year-over-year growth 2021-2026 (%)
Exhibit 45: Data Table on SSRIs - Year-over-year growth 2021-2026 (%)
6.4 PDE5 inhibitors - Market size and forecast 2021-2026
Exhibit 46: Chart on PDE5 inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 47: Data Table on PDE5 inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibit 48: Chart on PDE5 inhibitors - Year-over-year growth 2021-2026 (%)
Exhibit 49: Data Table on PDE5 inhibitors - Year-over-year growth 2021-2026 (%)
6.5 Amide anesthetics - Market size and forecast 2021-2026
Exhibit 50: Chart on Amide anesthetics - Market size and forecast 2021-2026 ($ million)
Exhibit 51: Data Table on Amide anesthetics - Market size and forecast 2021-2026 ($ million)
Exhibit 52: Chart on Amide anesthetics - Year-over-year growth 2021-2026 (%)
Exhibit 53: Data Table on Amide anesthetics - Year-over-year growth 2021-2026 (%)
6.6 Others - Market size and forecast 2021-2026
Exhibit 54: Chart on Others - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on Others - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on Others - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on Others - Year-over-year growth 2021-2026 (%)
6.7 Market opportunity by Drug Class
Exhibit 58: Market opportunity by Drug Class ($ million)
7 Customer Landscape
7.1 Customer landscape overview
Exhibit 59: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
8 Geographic Landscape
8.1 Geographic segmentation
Exhibit 60: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibit 61: Data Table on Market share By Geographical Landscape 2021-2026 (%)
8.2 Geographic comparison
Exhibit 62: Chart on Geographic comparison
Exhibit 63: Data Table on Geographic comparison
8.3 North America - Market size and forecast 2021-2026
Exhibit 64: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 65: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 66: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 67: Data Table on North America - Year-over-year growth 2021-2026 (%)
8.4 Europe - Market size and forecast 2021-2026
Exhibit 68: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 69: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 70: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 71: Data Table on Europe - Year-over-year growth 2021-2026 (%)
8.5 Asia - Market size and forecast 2021-2026
Exhibit 72: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 73: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 74: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 75: Data Table on Asia - Year-over-year growth 2021-2026 (%)
8.6 Rest of World (ROW) - Market size and forecast 2021-2026
Exhibit 76: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 77: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 78: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 79: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
8.7 US - Market size and forecast 2021-2026
Exhibit 80: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 81: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 82: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 83: Data Table on US - Year-over-year growth 2021-2026 (%)
8.8 Italy - Market size and forecast 2021-2026
Exhibit 84: Chart on Italy - Market size and forecast 2021-2026 ($ million)
Exhibit 85: Data Table on Italy - Market size and forecast 2021-2026 ($ million)
Exhibit 86: Chart on Italy - Year-over-year growth 2021-2026 (%)
Exhibit 87: Data Table on Italy - Year-over-year growth 2021-2026 (%)
8.9 China - Market size and forecast 2021-2026
Exhibit 88: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibit 89: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibit 90: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibit 91: Data Table on China - Year-over-year growth 2021-2026 (%)
8.10 UK - Market size and forecast 2021-2026
Exhibit 92: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 93: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 94: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibit 95: Data Table on UK - Year-over-year growth 2021-2026 (%)
8.11 India - Market size and forecast 2021-2026
Exhibit 96: Chart on India - Market size and forecast 2021-2026 ($ million)
Exhibit 97: Data Table on India - Market size and forecast 2021-2026 ($ million)
Exhibit 98: Chart on India - Year-over-year growth 2021-2026 (%)
Exhibit 99: Data Table on India - Year-over-year growth 2021-2026 (%)
8.12 Market opportunity By Geographical Landscape
Exhibit 100: Market opportunity By Geographical Landscape ($ million)
9 Drivers, Challenges, and Trends
9.1 Market drivers
9.2 Market challenges
9.3 Impact of drivers and challenges
Exhibit 101: Impact of drivers and challenges in 2021 and 2026
9.4 Market trends
10 Vendor Landscape
10.1 Overview
10.2 Vendor landscape
Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
10.3 Landscape disruption
Exhibit 103: Overview on factors of disruption
10.4 Industry risks
Exhibit 104: Impact of key risks on business
11 Vendor Analysis
11.1 Vendors covered
Exhibit 105: Vendors covered
11.2 Market positioning of vendors
Exhibit 106: Matrix on vendor position and classification
11.3 Absorption Pharmaceuticals LLC
Exhibit 107: Absorption Pharmaceuticals LLC - Overview
Exhibit 108: Absorption Pharmaceuticals LLC - Product / Service
Exhibit 109: Absorption Pharmaceuticals LLC - Key offerings
11.4 Alembic Pharmaceuticals Inc.
Exhibit 110: Alembic Pharmaceuticals Inc. - Overview
Exhibit 111: Alembic Pharmaceuticals Inc. - Product / Service
Exhibit 112: Alembic Pharmaceuticals Inc. - Key offerings
11.5 Amneal Pharmaceuticals Inc.
Exhibit 113: Amneal Pharmaceuticals Inc. - Overview
Exhibit 114: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 115: Amneal Pharmaceuticals Inc. - Key news
Exhibit 116: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 117: Amneal Pharmaceuticals Inc. - Segment focus
11.6 Bayer AG
Exhibit 118: Bayer AG - Overview
Exhibit 119: Bayer AG - Business segments
Exhibit 120: Bayer AG - Key offerings
Exhibit 121: Bayer AG - Segment focus
11.7 Cipla Ltd.
Exhibit 122: Cipla Ltd. - Overview
Exhibit 123: Cipla Ltd. - Business segments
Exhibit 124: Cipla Ltd. - Key news
Exhibit 125: Cipla Ltd. - Key offerings
Exhibit 126: Cipla Ltd. - Segment focus
11.8 Eli Lilly and Co.
Exhibit 127: Eli Lilly and Co. - Overview
Exhibit 128: Eli Lilly and Co. - Product / Service
Exhibit 129: Eli Lilly and Co. - Key offerings
11.9 Pfizer Inc.
Exhibit 130: Pfizer Inc. - Overview
Exhibit 131: Pfizer Inc. - Product / Service
Exhibit 132: Pfizer Inc. - Key news
Exhibit 133: Pfizer Inc. - Key offerings
11.10 Sandoz International GmbH
Exhibit 134: Sandoz International GmbH - Overview
Exhibit 135: Sandoz International GmbH - Product / Service
Exhibit 136: Sandoz International GmbH - Key news
Exhibit 137: Sandoz International GmbH - Key offerings
11.11 Solco Healthcare
Exhibit 138: Solco Healthcare - Overview
Exhibit 139: Solco Healthcare - Product / Service
Exhibit 140: Solco Healthcare - Key offerings
11.12 Teva Pharmaceutical Industries Ltd.
Exhibit 141: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 142: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 143: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 144: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 145: Teva Pharmaceutical Industries Ltd. - Segment focus
12 Appendix
12.1 Scope of the report
12.2 Inclusions and exclusions checklist
Exhibit 146: Inclusions checklist
Exhibit 147: Exclusions checklist
12.3 Currency conversion rates for US$
Exhibit 148: Currency conversion rates for US$
12.4 Research methodology
Exhibit 149: Research methodology
Exhibit 150: Validation techniques employed for market sizing
Exhibit 151: Information sources
12.5 List of abbreviations
Exhibit 152: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits 6: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 18: Five forces analysis - Comparison between 2021 and 2026
Exhibits 19: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
Exhibits 20: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
Exhibits 21: Threat of new entrants - Impact of key factors in 2021 and 2026
Exhibits 22: Threat of substitutes - Impact of key factors in 2021 and 2026
Exhibits 23: Threat of rivalry - Impact of key factors in 2021 and 2026
Exhibits 24: Chart on Market condition - Five forces 2021 and 2026
Exhibits 25: Chart on Route of Administration - Market share 2021-2026 (%)
Exhibits 26: Data Table on Route of Administration - Market share 2021-2026 (%)
Exhibits 27: Chart on Comparison by Route of Administration
Exhibits 28: Data Table on Comparison by Route of Administration
Exhibits 29: Chart on Oral - Market size and forecast 2021-2026 ($ million)
Exhibits 30: Data Table on Oral - Market size and forecast 2021-2026 ($ million)
Exhibits 31: Chart on Oral - Year-over-year growth 2021-2026 (%)
Exhibits 32: Data Table on Oral - Year-over-year growth 2021-2026 (%)
Exhibits 33: Chart on Topical - Market size and forecast 2021-2026 ($ million)
Exhibits 34: Data Table on Topical - Market size and forecast 2021-2026 ($ million)
Exhibits 35: Chart on Topical - Year-over-year growth 2021-2026 (%)
Exhibits 36: Data Table on Topical - Year-over-year growth 2021-2026 (%)
Exhibits 37: Market opportunity by Route of Administration ($ million)
Exhibits 38: Chart on Drug Class - Market share 2021-2026 (%)
Exhibits 39: Data Table on Drug Class - Market share 2021-2026 (%)
Exhibits 40: Chart on Comparison by Drug Class
Exhibits 41: Data Table on Comparison by Drug Class
Exhibits 42: Chart on SSRIs - Market size and forecast 2021-2026 ($ million)
Exhibits 43: Data Table on SSRIs - Market size and forecast 2021-2026 ($ million)
Exhibits 44: Chart on SSRIs - Year-over-year growth 2021-2026 (%)
Exhibits 45: Data Table on SSRIs - Year-over-year growth 2021-2026 (%)
Exhibits 46: Chart on PDE5 inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibits 47: Data Table on PDE5 inhibitors - Market size and forecast 2021-2026 ($ million)
Exhibits 48: Chart on PDE5 inhibitors - Year-over-year growth 2021-2026 (%)
Exhibits 49: Data Table on PDE5 inhibitors - Year-over-year growth 2021-2026 (%)
Exhibits 50: Chart on Amide anesthetics - Market size and forecast 2021-2026 ($ million)
Exhibits 51: Data Table on Amide anesthetics - Market size and forecast 2021-2026 ($ million)
Exhibits 52: Chart on Amide anesthetics - Year-over-year growth 2021-2026 (%)
Exhibits 53: Data Table on Amide anesthetics - Year-over-year growth 2021-2026 (%)
Exhibits 54: Chart on Others - Market size and forecast 2021-2026 ($ million)
Exhibits 55: Data Table on Others - Market size and forecast 2021-2026 ($ million)
Exhibits 56: Chart on Others - Year-over-year growth 2021-2026 (%)
Exhibits 57: Data Table on Others - Year-over-year growth 2021-2026 (%)
Exhibits 58: Market opportunity by Drug Class ($ million)
Exhibits 59: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 60: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 61: Data Table on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 62: Chart on Geographic comparison
Exhibits 63: Data Table on Geographic comparison
Exhibits 64: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 65: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 66: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibits 67: Data Table on North America - Year-over-year growth 2021-2026 (%)
Exhibits 68: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 69: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 70: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 71: Data Table on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 72: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits 73: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits 74: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibits 75: Data Table on Asia - Year-over-year growth 2021-2026 (%)
Exhibits 76: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits 77: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits 78: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits 79: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits 80: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibits 81: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibits 82: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibits 83: Data Table on US - Year-over-year growth 2021-2026 (%)
Exhibits 84: Chart on Italy - Market size and forecast 2021-2026 ($ million)
Exhibits 85: Data Table on Italy - Market size and forecast 2021-2026 ($ million)
Exhibits 86: Chart on Italy - Year-over-year growth 2021-2026 (%)
Exhibits 87: Data Table on Italy - Year-over-year growth 2021-2026 (%)
Exhibits 88: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibits 89: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibits 90: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibits 91: Data Table on China - Year-over-year growth 2021-2026 (%)
Exhibits 92: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibits 93: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibits 94: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibits 95: Data Table on UK - Year-over-year growth 2021-2026 (%)
Exhibits 96: Chart on India - Market size and forecast 2021-2026 ($ million)
Exhibits 97: Data Table on India - Market size and forecast 2021-2026 ($ million)
Exhibits 98: Chart on India - Year-over-year growth 2021-2026 (%)
Exhibits 99: Data Table on India - Year-over-year growth 2021-2026 (%)
Exhibits 100: Market opportunity By Geographical Landscape ($ million)
Exhibits 101: Impact of drivers and challenges in 2021 and 2026
Exhibits 102: Overview on Criticality of inputs and Factors of differentiation
Exhibits 103: Overview on factors of disruption
Exhibits 104: Impact of key risks on business
Exhibits 105: Vendors covered
Exhibits 106: Matrix on vendor position and classification
Exhibits 107: Absorption Pharmaceuticals LLC - Overview
Exhibits 108: Absorption Pharmaceuticals LLC - Product / Service
Exhibits 109: Absorption Pharmaceuticals LLC - Key offerings
Exhibits 110: Alembic Pharmaceuticals Inc. - Overview
Exhibits 111: Alembic Pharmaceuticals Inc. - Product / Service
Exhibits 112: Alembic Pharmaceuticals Inc. - Key offerings
Exhibits 113: Amneal Pharmaceuticals Inc. - Overview
Exhibits 114: Amneal Pharmaceuticals Inc. - Business segments
Exhibits 115: Amneal Pharmaceuticals Inc. - Key news
Exhibits 116: Amneal Pharmaceuticals Inc. - Key offerings
Exhibits 117: Amneal Pharmaceuticals Inc. - Segment focus
Exhibits 118: Bayer AG - Overview
Exhibits 119: Bayer AG - Business segments
Exhibits 120: Bayer AG - Key offerings
Exhibits 121: Bayer AG - Segment focus
Exhibits 122: Cipla Ltd. - Overview
Exhibits 123: Cipla Ltd. - Business segments
Exhibits 124: Cipla Ltd. - Key news
Exhibits 125: Cipla Ltd. - Key offerings
Exhibits 126: Cipla Ltd. - Segment focus
Exhibits 127: Eli Lilly and Co. - Overview
Exhibits 128: Eli Lilly and Co. - Product / Service
Exhibits 129: Eli Lilly and Co. - Key offerings
Exhibits 130: Pfizer Inc. - Overview
Exhibits 131: Pfizer Inc. - Product / Service
Exhibits 132: Pfizer Inc. - Key news
Exhibits 133: Pfizer Inc. - Key offerings
Exhibits 134: Sandoz International GmbH - Overview
Exhibits 135: Sandoz International GmbH - Product / Service
Exhibits 136: Sandoz International GmbH - Key news
Exhibits 137: Sandoz International GmbH - Key offerings
Exhibits 138: Solco Healthcare - Overview
Exhibits 139: Solco Healthcare - Product / Service
Exhibits 140: Solco Healthcare - Key offerings
Exhibits 141: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits 142: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits 143: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits 144: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits 145: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits 146: Inclusions checklist
Exhibits 147: Exclusions checklist
Exhibits 148: Currency conversion rates for US$
Exhibits 149: Research methodology
Exhibits 150: Validation techniques employed for market sizing
Exhibits 151: Information sources
Exhibits 152: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global premature ejaculation treatment market: A. Menarini Industrie Farmaceutiche Riunite Srl, Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., ANI Pharmaceuticals Inc., Aytu BioPharma Inc., Bayer AG, Cipla Ltd., Eli Lilly and Co., Endurance RP Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Lupin Ltd., NeuroHealing Pharmaceuticals Inc., Novitium Pharma, Pfizer Inc., Plethora Solutions Ltd., Sandoz International GmbH, Solco Healthcare, and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is the advent of nanotechnology.`

According to the report, one of the major drivers for this market is the high efficacy of off-label drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Absorption Pharmaceuticals LLC
  • Alembic Pharmaceuticals Inc.
  • Amneal Pharmaceuticals Inc.
  • ANI Pharmaceuticals Inc.
  • Aytu BioPharma Inc.
  • Bayer AG
  • Cipla Ltd.
  • Eli Lilly and Co.
  • Endurance RP Ltd.
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • Lupin Ltd.
  • NeuroHealing Pharmaceuticals Inc.
  • Novitium Pharma
  • Pfizer Inc.
  • Plethora Solutions Ltd.
  • Sandoz International GmbH
  • Solco Healthcare
  • Teva Pharmaceutical Industries Ltd.